How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,011 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Fluconazole

were studied at the Gynecological Clinic of Peking University Shenzhen Hospital from January 1, 2009 through December 31, 2010. Patients with SVVC were treated with two doses of miconazole 2015 11. Comparative clinical trial: fluconazole alone or associated with topical ketoconazole in the treatment of pityriasis versicolor. 27532525 2016 08 18 2017 01 10 2017 01 11 0041-4131 94 2 2016 Feb La Tunisie medicale Tunis Med Comparative clinical trial: fluconazole alone or associated with topical (...) ketoconazole in the treatment of pityriasis versicolor. 107-11 The efficacy of ketoconazole and fluconazole in pityriasis versicolor had been proved. To compare the efficacy and the safety of two doses (...) of fluconazole given 1 week apart alone or associated to ketoconazole shampoo. Our study included all patients with pityriasis versicolor who attended in dermatology department of Habib Thameur Hospital, Tunis (over a 21-month period). During the considered period, patients were randomly assigned

2018 Trip Latest and Greatest

202. Budesonide (Jorveza) - to treat adults with eosinophilic oesophagitis

is not a substrate for OATP1B3. Assessment report EMA/774645/2017 Page 23/83 Conversely in vitro interaction studies (Lu et al.: Drug Metab Dispos 2008 and Jönsson et al.: Drug Metab Dispos. 1995) have demonstrated strong inhibition of the metabolic degradation of budesonide by specific inhibitors of CYP3A4; i.e. ketoconazole. Contrary to CYP3A4 inhibitors, compounds or drugs such as carbamazepine and rifampicin, which are able to induce CYP3A4, might reduce the systemic exposure but probably also the local (...) 850.1500) by end of 2018, to which the applicant committed. 2.3.6. Discussion on non-clinical aspects The literature review on the safety pharmacology of budesonide is considered adequate. In vitro studies have demonstrated strong inhibition of the metabolic degradation of budesonide by specific inhibitors of CYP3A4; i.e. ketoconazole. In humans a clear influence of ketoconazole on the pharmacokinetics of budesonide was observed. The Applicant pointed out that a potential inhibition of the metabolic

2018 European Medicines Agency - EPARs

203. Antiplatelet medicines

. However, the risks should still be borne in mind and the patient should be closely monitored. Concomitant use of antiplatelet medicines with NSAIDs and/or SSRIs also increases the risk of bleeding. 5 Ticagrelor levels, and therefore the risk of bleeding, are increased where ‘strong’ CYP3A4 inhibitors are co-prescribed. Co-administration of ticagrelor with ritonavir, ketoconazole, clarithromycin, nefazodone, or atazanavir is contraindicated. 5 Decreased efficacy There is some evidence that the effect

2018 WeMeReC

204. Treatment algorithm for Cancer-associated Thrombosis (CAT)

agents Vinblastine ? ? ? Anti-mycotic agents Azithromycin ? ? ? Clarithromycin ? ? ? Erythromycin ? ? ? Itroconazole ? ? ? Ketoconazole ? ? ? Posaconazole — ? ? Voriconazole — ? ? Anthracyclines Doxorubicin ? ? ? Hormonal agents Tamoxifen ? ? ? Immune-modulating agents Cyclosporine ? ? ? Dexamethasone ? ? ? Tacrolimus ? ? ? Protease inhibitors Indinavir ? ? ? Nelfinavir ? ? ? Ritonavir ? ? ? Saquinavir ? ? ? Tyrosine kinase inhibitors Imatinib — ? ? Lapatinib ? ? ? Nilotinib ? ? ? Sunitinib

2018 Thrombosis Interest Group of Canada

205. Guanfacine (Intuniv) for attention deficit hyperactivity disorder Full Text available with Trip Pro

to 24 hours for the development of more serious toxicity (including coma, bradycardia, and hypotension) due to the possibility of delayed onset of these symptoms. For information about reporting adverse reactions to the TGA, or to report suspected adverse reactions online, see the . Drug interactions Guanfacine is a substrate of CYP3A4/3A5 and caution is required if it is co-administered with CYP3A4/3A5 inducers (such as rifampicin) and inhibitors (such as ketoconazole). Co-administration

2019 National Prescribing Service Limited (Australia)

209. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis

of antifungal susceptibility testing should take into account the acid pH of the vagina compared with the neutral pH at which testing is usually performed; the activity of azole antifungals is reduced in acidic environment and clinical resistance may occur despite the isolate being microbiologically susceptible. Treatment: • Oral azoles – continue to avoid in pregnancy, at risk of pregnancy and whilst breastfeeding • Ketoconazole is no longer recommended for the treatment of VVC • Non-azole therapies (...) does not support the use of low dose protracted regimens such as fluconazole 50mg od for 14- 28 days for recurrent VVC and suggests there is potential for development of antifungal resistance 98 • There is a low risk of idiosyncratic drug-induced hepatitis with oral azoles, although fluconazole is less frequently associated with hepatotoxicity than itraconazole (see later ‘Reactions to treatment’); • Oral ketoconazole is no longer recommended for the treatment of fungal infections due to the risk

2019 British Association for Sexual Health and HIV

210. Emergency management of adrenal insufficiency in children: advocating for treatment options in outpatient and field settings

suppress the hypothalamic-pi- tuitary-adrenal (HPA) axis. 9 10 Other medications, such as megestrol acetate, ketoconazole, and mifepristone, also impair adrenal function via direct and indirect mecha- nisms. Less common secondary causes of ACTH deficiency involving the pituitary and hypothalamus include tumors, radiation exposure, congenital anomalies, and specific gene defects (table 1 and box 1). Inherited forms of ACTH deficiency are usually associated with additional pituitary hormone deficiencies (...) polyendocrinopathy type 2. ? Bilateral hemorrhage/infarction – Trauma. – Waterhouse-Friderichsen syndrome. – Anticoagulation. ? Drug effect: mifepristone, aminoglutethimide, mitotane, ketoconazole, etomidate, metyrapone, rifampin, phenytoin, barbiturates, tyrosine kinase inhibitors (eg, sunitinib) ? Infection – Viral: HIV, cytomegalovirus. – Fungal: coccidioidomycosis, histoplasmosis, blastomycosis, cryptococcosis. – Mycobacterial: tuberculosis. – Amebic. ? Infiltrative – Hemochromatosis, histiocytosis

2019 Pediatric Endocrine Society

213. Comparative evaluation of ketoconazole tablet and topical ketoconazole 2% in orabase in treatment of Candida-infected denture stomatitis. (Abstract)

Comparative evaluation of ketoconazole tablet and topical ketoconazole 2% in orabase in treatment of Candida-infected denture stomatitis. Denture stomatitis is a common and recurring problem of denture wearers. Ketoconazole tablet is one of the antimycotic drugs that often has been used to treat this condition, but systemic use of this drug has some adverse effects that frequently lead to unfavorable compliance and treatment failure. This study was designed to compare the efficacy of topical (...) ketoconazole 2% in orabase and ketoconazole tablet.Thirty patients with denture stomatitis (positive culture) were divided into two groups. The first group received ketoconazole tablet (orally used 200 mg per day) for 14 days and the second group received 2% topical ketoconazole in orabase applied twice daily on the mucosal denture surface. Candida cultures were taken from the palatal mucosa before and on days 7 and 14 after commencement of the therapy. The mean of colonies before and 7 and 14 days after

2010 The journal of contemporary dental practice Controlled trial quality: uncertain

214. Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo

Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo - Full Text View - Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. Identifier: NCT01203189 Recruitment Status : Completed First Posted : September 16, 2010 Results First Posted : November 6, 2017 Last Update Posted : November 6, 2017 Sponsor: St. Louis University

2010 Clinical Trials

215. Grazoprevir with elbasvir (Zepatier): fixed-dose combination for chronic hepatitis C genotypes 1 and 4

concentration. This can increase the risk of ALT elevations. GRZ/EBR is contraindicated with OATP1B1/3 inhibitors that are known or expected to significantly increase grazoprevir plasma concentrations, including: rifampicin atazanavir, darunavir, lopinavir, saquinavir and tipranavir ciclosporin. Precautions Caution should be used when co-administering GRZ/EBR with: strong cytochrome P450 3A4 inhibitors (eg, ketoconazole and ritonavir), which may lead to increased concentrations of elbasvir and grazoprevir

2018 National Prescribing Service Limited (Australia)

216. CRACKCast E184 – The Solid Organ Transplant Donor

, Diltiazem, Fluconazole, Fluoroquinolones, Ketoconazole, Macrolide antibiotics, Oral contraceptives, Verapamil Interact at a glomerular or tubular level (increased nephrotoxicity). E.g., Aminoglycosides, Amphotericin B, Cimetidine, Nonsteroidals, Sulfur This post was copyedited and uploaded by Samuel Hogman (Visited 577 times, 1 visits today) Chris Lipp is one of the founding Fathers for CrackCast. He currently divides his time as an EM Physician in Calgary (SHC/FMC) and in Sports Medicine. His interests

2018 CandiEM

220. Castration-Resistant Prostate Cancer

developed to provide a rational basis for treatment based on currently available published data. [pdf] [pdf] [pdf] Note to the Reader: On July 21, 2014, the FDA issued a recommendation that health care professionals should consider the alcohol content of docetaxel when prescribing or administering the drug to patients. On July 26, 2013, the FDA issued a safety announcement related to the use of ketoconazole in the form of oral tablets. Side effects can include hepatotoxicity, adrenal insufficiency (...) ; Evidence Level Grade C) Index Patient 2 5. Clinicians should offer abiraterone plus prednisone, enzalutamide, docetaxel, or sipuleucel-T to patients with asymptomatic or minimally symptomatic mCRPC with good performance status and no prior docetaxel chemotherapy. (Standard; Evidence Level Grade A [abiraterone plus prednisone and enzalutamide] /B [docetaxel and sipuleucel-T]) 6. Clinicians may offer first- generation anti-androgen therapy, ketoconazole plus steroid or observation to patients

2018 American Urological Association

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>